Your browser doesn't support javascript.
loading
Anti-obesity drugs: status quo and recent advances / 中国医学科学院学报
Acta Academiae Medicinae Sinicae ; (6): 243-247, 2011.
Article Dans Anglais | WPRIM | ID: wpr-341422
ABSTRACT
Obesity has become a major health problem worldwide. The prevalence and morbidity of obesity-related diseases including diabetes, hypertension, cerebro-cardiovascular diseases, and tumors also have remarkably increased. Treatment of obesity poses a challenge for clinicians. Anti-obesity treatment is helpful to improve and even reverse obesity-related complications. Diet control and physical exercises remain the predominant interventions for obese patients. Anti-obesity drugs can be considered in those who respond poorly to behavioral intervention or those who have developed obesity-related complications. The commonly used anti-obesity drugs include gastrointestinal lipase inhibitors and appetite suppressants. Glucagon-like peptide 1 has also been found to be effective in reducing body weight. Some more drugs are under development, which include selective 5-HT 2c agonist, β3 receptor agonist, and melanocortin receptor 4 agonist, may also be promising.
Sujets)
Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Anorexigènes / Agents antiobésité / Utilisations thérapeutiques / Traitement médicamenteux / Glucagon-like peptide 1 / Obésité Limites du sujet: Humains langue: Anglais Texte intégral: Acta Academiae Medicinae Sinicae Année: 2011 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Anorexigènes / Agents antiobésité / Utilisations thérapeutiques / Traitement médicamenteux / Glucagon-like peptide 1 / Obésité Limites du sujet: Humains langue: Anglais Texte intégral: Acta Academiae Medicinae Sinicae Année: 2011 Type: Article